Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metreleptin immunogenicity in generalized lipodystrophy
NCT04026178Phase 4Completed
- Sponsor
- Aegerion Pharmaceuticals
- Start
- Nov 2018
- Primary completion
- Oct 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of metreleptin in generalized lipodystrophy (GL), sponsored by Aegerion Pharmaceuticals. Started Nov 2018; status: completed.
02
Drugs
metreleptin
03
Conditions
generalized lipodystrophy (GL)
Beyond the preview
Go deeper on NCT04026178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04026178.